Template:Herpes antiviral treatment: Difference between revisions
Neil.m.young (talk | contribs) (current recs from CDC) |
Neil.m.young (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
*[[Acyclovir]] OR | *[[Acyclovir]] OR | ||
**400mg PO q8hrs x 7-10 days | **400mg PO q8hrs x 7-10 days | ||
**''or''200mg PO 5x/day x 7-10 days | **''or'' 200mg PO 5x/day x 7-10 days | ||
*[[Valacyclovir]] 1g PO q12hrs x 7-10 days OR | *[[Valacyclovir]] 1g PO q12hrs x 7-10 days OR | ||
*[[Famciclovir]] 250mg PO q8hrs x 7-10 days | *[[Famciclovir]] 250mg PO q8hrs x 7-10 days | ||
Revision as of 06:49, 5 June 2015
Initial Episode[1]
- Acyclovir OR
- 400mg PO q8hrs x 7-10 days
- or 200mg PO 5x/day x 7-10 days
- Valacyclovir 1g PO q12hrs x 7-10 days OR
- Famciclovir 250mg PO q8hrs x 7-10 days
Recurrence
- Valacyclovir OR
- 500mg PO q12hrs x 3 days
- or 1g PO qd x 5 days
- Acyclovir 800mg PO q12hrs x 5 days OR
- Famciclovir 1g PO q12hrs for 1 day
Suppressive Therapy
- Acyclovir 400mg PO q12hrs daily OR
- Famciclovir 250mg PO q12hrs daily OR
- Valacyclovir 1g PO daily
- ↑ Workoski KA and Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommen and Reports. 2015; 64(3):1-140.